AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Pridinol acts centrally on the nervous system to induce muscle relaxation. It helps alleviate muscle spasms, stiffness, and tension, thereby improving mobility and reducing discomfort associated with musculoskeletal conditions.
Antispasmodic Effects: Pridinol exerts antispasmodic effects by inhibiting the excessive contraction of muscles. It is particularly useful in the treatment of conditions characterized by abnormal or involuntary muscle contractions, such as muscle spasms, cramps, and dystonia.
Pain Relief: By promoting muscle relaxation and reducing muscle spasms, pridinol can help alleviate associated pain symptoms. It may be used as an adjunctive therapy in the management of acute and chronic musculoskeletal pain conditions.
Adjunctive Therapy: Pridinol is often used as an adjunctive therapy alongside other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or physical therapy, to enhance the overall management of musculoskeletal disorders.
Safety Profile: Pridinol is generally well-tolerated when used at recommended dosages. Common side effects may include drowsiness, dizziness, dry mouth, blurred vision, and gastrointestinal disturbances. These side effects are usually mild and transient.
Central Nervous System Effects: Due to its central nervous system activity, pridinol may cause sedation or drowsiness, particularly at higher doses. Patients should be advised to avoid activities requiring mental alertness, such as driving or operating heavy machinery, until they know how the medication affects them.
Contraindications: Pridinol is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should be used with caution in patients with certain medical conditions, such as glaucoma, urinary retention, or severe hepatic or renal impairment.
Drug Interactions: Pridinol may interact with other medications that have sedative or CNS depressant effects, including alcohol, benzodiazepines, and opioids. Healthcare providers should assess potential drug interactions and adjust dosages accordingly when prescribing pridinol.
Pregnancy and Lactation: The safety of pridinol use during pregnancy and lactation has not been well-established. Pregnant or breastfeeding women should consult their healthcare provider before using pridinol.
Overdose: In cases of overdose or excessive ingestion of pridinol, symptoms may include severe CNS depression, respiratory depression, hypotension, and coma. Immediate medical attention is necessary if overdose is suspected.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.7 | 1.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.3 | -2 |
| Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | |
| Allergies | 1.5 | 0.4 | 2.75 |
| Allergy to milk products | 0.9 | 0.5 | 0.8 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 3 | 2.2 | 0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.5 | 1.4 |
| Ankylosing spondylitis | 1.5 | 0.9 | 0.67 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 0.6 | -0.6 | |
| Atherosclerosis | 0.3 | 0.4 | -0.33 |
| Atrial fibrillation | 0.7 | 1.7 | -1.43 |
| Autism | 3 | 3.8 | -0.27 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 1.3 | 0.1 | 12 |
| Brain Trauma | 0.6 | -0.6 | |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 2 | 1 | 1 |
| Cerebral Palsy | 0.1 | 0.6 | -5 |
| Chronic Fatigue Syndrome | 1.8 | 2.5 | -0.39 |
| Chronic Kidney Disease | 1.1 | 0.1 | 10 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.1 | 5 |
| Chronic Urticaria (Hives) | 0.8 | 1.3 | -0.63 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 0.2 | 4.5 |
| Colorectal Cancer | 3.6 | 3.6 | |
| Constipation | 1.7 | 0.1 | 16 |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 4.2 | 4 | 0.05 |
| Crohn's Disease | 5 | 2.1 | 1.38 |
| cystic fibrosis | 0.8 | 0.6 | 0.33 |
| deep vein thrombosis | 0.8 | 0.2 | 3 |
| Depression | 4.2 | 1.8 | 1.33 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.4 | 1.1 | -1.75 |
| Endometriosis | 1.5 | 1.5 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 2 | 1.4 | 0.43 |
| Fibromyalgia | 1.1 | 1.8 | -0.64 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 1.9 | 0.95 |
| gallstone disease (gsd) | 0.5 | 0.5 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 0.1 | 22 |
| Generalized anxiety disorder | 1.2 | 0.4 | 2 |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.7 | 0.1 | 6 |
| Halitosis | 0.8 | 0.1 | 7 |
| Hashimoto's thyroiditis | 0.6 | 0.8 | -0.33 |
| Hidradenitis Suppurativa | 0.7 | 0.7 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.6 | 0.1 | 15 |
| hyperglycemia | 0.3 | 0.7 | -1.33 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1 | 1.9 | -0.9 |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 2.2 | -2.2 | |
| Inflammatory Bowel Disease | 2.4 | 2.5 | -0.04 |
| Insomnia | 0.5 | 0.6 | -0.2 |
| Intelligence | 1 | 0.4 | 1.5 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.9 | 2.8 | -0.47 |
| Liver Cirrhosis | 1.8 | 1 | 0.8 |
| Long COVID | 3.1 | 2.1 | 0.48 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.1 | 0.4 | -3 |
| ME/CFS without IBS | 0.3 | 0.7 | -1.33 |
| Metabolic Syndrome | 3.4 | 4.5 | -0.32 |
| Mood Disorders | 4.5 | 1.8 | 1.5 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 1.2 | 2.5 | -1.08 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| Neuropathy (all types) | 0.1 | 0.3 | -2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.4 | 0.75 |
| Obesity | 1.6 | 1.1 | 0.45 |
| obsessive-compulsive disorder | 4.4 | 1 | 3.4 |
| Osteoarthritis | 0.9 | 0.9 | |
| Osteoporosis | 0.7 | 0.4 | 0.75 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 1.2 | 2 | -0.67 |
| Polycystic ovary syndrome | 1.9 | 0.1 | 18 |
| Premenstrual dysphoric disorder | 0.3 | -0.3 | |
| primary biliary cholangitis | 1 | -1 | |
| Psoriasis | 1.5 | 1.5 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.7 | 1.9 | 0.42 |
| Rosacea | 0.1 | -0.1 | |
| Schizophrenia | 2 | 0.1 | 19 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.9 | 1.7 | -0.89 |
| Sleep Apnea | 0.3 | 0.6 | -1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.7 | 0.6 | 1.83 |
| Systemic Lupus Erythematosus | 2.8 | 0.1 | 27 |
| Tic Disorder | 1 | 0.4 | 1.5 |
| Tourette syndrome | 0.4 | -0.4 | |
| Type 1 Diabetes | 3 | 1.2 | 1.5 |
| Type 2 Diabetes | 4.4 | 5.3 | -0.2 |
| Ulcerative colitis | 1.2 | 3.5 | -1.92 |
| Unhealthy Ageing | 3.9 | 0.1 | 38 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.